| Literature DB >> 34393507 |
Na Zhang1,2, Jian-Feng Tu1, Ying Lin1, Jin-Ling Li1, Xuan Zou1, Yu Wang1, Hewen Li1, Xiao-Ya Wei1, Li-Qiong Wang1, Guang-Xia Shi1, Shi-Yan Yan1, Cun-Zhi Liu1.
Abstract
BACKGROUND: Whether the clinical effect of acupuncture in chronic pain is effective has always been a hot topic of research, which has a great relationship with the overall reporting descriptions of acupuncture, especially the sham acupuncture intervention. To confirm the effectiveness of acupuncture, more clinical studies are often required. Therefore, it is necessary to report high-quality and complete descriptions of acupuncture in clinical trials. This study aims to assess the overall reporting quality of acupuncture for chronic pain in randomized controlled trials (RCTs).Entities:
Keywords: chronic pain; overall reporting quality; randomized controlled trials; sham acupuncture
Year: 2021 PMID: 34393507 PMCID: PMC8354735 DOI: 10.2147/JPR.S319195
Source DB: PubMed Journal: J Pain Res ISSN: 1178-7090 Impact factor: 3.133
Figure 1The PRISMA flow diagram.
Notes: PRISMA figure adapted from Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of clinical epidemiology. 2009;62(10). Creative Commons.20
Figure 2Number of published articles per year (n=74).
Figure 3The proportion of diseases in literature (n=74).
Pain Checklist Supplement (n=74)
| Item | Description | Number of Positive Trials (n) | Percentage (%) |
|---|---|---|---|
| Methods | |||
| 1. Participants | Clear definition of entry criteria | 67 | 90.54 |
| 2. Outcomes | Prespecified primary outcome measure (including type of pain measure [eg, NRS or VAS], characteristics of pain [eg, average, and worst], time frame of measure, and additional instructions provided [eg, location of pain]) | 74 | 100.00 |
| Secondary outcome measures (indicate if prespecified or not) | |||
| Any participant training in regards to responding to included patient-reported outcome measures | |||
| 3. Blinding | Who, if anyone, was blinded (eg, participants, all investigators, outcome assessors) and what they were blinded to (eg, treatment assignment and study hypotheses) | 57 | 77.03 |
| Efforts made to enhance blinding (eg, active placebo treatments) | |||
| Efforts made to maximize the similarities between the active and control study procedures in behavioral and procedural trails, including efforts made to elicit similar outcome expectancies | |||
| Attempts made to blind investigators to eligibility criteria | |||
| 4. Statistical methods | Primary analysis (including the time point [if applicable], statistical test(s), groups to be compared, and sample of participants). | 39 | 52.70 |
| For a “responder” analysis, provide a clear operational definition of “responder” | |||
| If multiple primary analyses, methods used to adjust for multiplicity or a statement that no adjustment was made with reasoning | |||
| Adjustments made for multiplicity in secondary analyses, if any | |||
| Methods used to accommodate missingdata and their underlying assumptions | |||
| Results | |||
| 5. Participant flow | Numbers screened and summary of major reasons for screen failure and refusal to participate | 52 | 70.27 |
Rating of Overall Quality Using Items from the STRICTA Guideline (n=74)
| Item | Criteria | Description | Number of Positive Trials | Percentage (%) |
|---|---|---|---|---|
| 1 | Acupuncture rationale | (1a) Style of acupuncture (eg, traditional Chinese medicine, Japanese, Korean, Western medical, five element, ear acupuncture, etc.) | 71 | 95.95 |
| (1b) Reasoning for treatment provided, based on historical context, literature sources and/or consensus methods, with references where appropriate | 70 | 94.59 | ||
| (1c) Extent to which treatment was varied | 0 | 0.00 | ||
| 2 | Details of needling | (2a) Number of needle insertions per subject per session (mean and range where relevant) | 72 | 97.30 |
| (2b) Names (or location if no standard name) of points used (uni-/bilateral) | 72 | 97.30 | ||
| (2c) Depth of insertion, based on a specified unit of measurement or on a particular tissue level | 40 | 54.05 | ||
| (2d) Responses sought (eg, de qi or muscle twitch response) | 68 | 91.89 | ||
| (2e) Needle stimulation (eg, manual or electrical) | 74 | 100.00 | ||
| (2f) Needle retention time | 73 | 98.65 | ||
| (2g) Needle type (diameter, length and manufacturer or material) | 42 | 56.76 | ||
| 3 | Treatment regimen | (3a) Number of treatment sessions | 74 | 100.00 |
| (3b) Frequency and duration of treatment sessions | 73 | 98.65 | ||
| 4 | Other components of treatment | (4a) Details of other interventions administered to the acupuncture group (eg, moxibustion, cupping, herbs, exercises, lifestyle advice) | 74 | 100.00 |
| (4b) Setting and context of treatment, including instructions to practitioners, and information and explanations to patients | 0 | 0.00 | ||
| 5 | Practitioner background | (5) Description of participating acupuncturists (qualification or professional affiliation, years in acupuncture practice, other relevant experience) | 59 | 79.73 |
Figure 4The proportions of articles (n=74) that met the criteria for each TIDieR-placebo item.